Palisade Bio price to sales ratio PALI

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 22.9×; May 2024
9-year median: 30.0×
9-year range: 8.3× to 192×
Peer median: 2.5×

Palisade Bio's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in May 2024, at 22.9×.

On the days it had one over the last 9 years, its median was 30.0×, from 8.3× in Aug 2019 to 192× in Oct 2019.

Price to sales ratio over time

median 30×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	22.9×	14.0×	26.4×
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	163×	163×	171×
2019	160×	8.3×	192×
2018	11.5×	11.5×	104×
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	n/m a value too high to mean anything
2013	198×	105×	198×
2012	108×	39.0×	123×

Against its peers

Companies in Biotechnology nearest Palisade Bio's size, closest first, today.

Company	Price to sales ratio
PALIPalisade Bio	n/m
PLXProtalix BioTherapeutics	2.5×
MGTXMeiraGTx	2.2×
VCELVericel	7.1×
Peer median	2.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Palisade Bio

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.